Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.

Overview

Study clinical multicenter, phase III, open-label, prospective character to evaluate the efficacy and safety Susanna Implant in patients with refractory glaucoma.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2011

Detailed Description

Clinical trial multicenter, phase III,open-label, prospective character to evaluate the efficacy and safety of Susanna Implant in patients with refractory glaucoma of both genders, of any race, aged above 18 years and diagnosed with glaucoma refractory.

Interventions

  • Device: Susanna Implant
    • device

Arms, Groups and Cohorts

  • No Intervention: Susanna Implant
    • Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.

Clinical Trial Outcome Measures

Primary Measures

  • Study clinical multicenter, phase III, open-label, prospective character to evaluate the efficacy and safety Susanna implant in patients with refractory glaucoma.
    • Time Frame: 180 days
    • Evaluate the effectiveness of implant susanna in patients with refractory glaucoma.

Secondary Measures

  • Study clinical multicenter, phase III, open-label, prospective character to evaluate the efficacy and safety Susanna implant in patients with refractory glaucoma. “
    • Time Frame: 180 days
    • Evaluate the safety of implant susanna in patients with refractory glaucoma. i

Participating in This Clinical Trial

Inclusion Criteria

Neovascular glaucoma group: 1. Patient with neovascular glaucoma whose intraocular pressures which must be above 21 in at least three measurements, at different times in at least two different days during one month, despite maximum tolerated medical therapy. 2. Visual acuity better than hand movements in the study eye. 3. Patients 18 years or more. 4. Patients with fixed residence in the health district where the surgery will be performed. 5. Patients who fit the term of consent. Group post-trabeculectomy failure: 1. Patients diagnosed with primary open angle glaucoma, pseudoesfoliação, pigmented or primary angle closure who underwent surgery with trabeculectomy procedure after failure of at least two months of surgery. The pressure must be above 21 in at least three measurements, at different times in at least two different days during one month, despite maximum tolerated medical therapy. 2. Patients diagnosed with primary open angle glaucoma, pseudoesfoliação, pigmented or primary angle closure who underwent surgery with trabeculectomy procedure after failure of at least two months for surgery and who can not afford the expenses of medical treatment. The pressure must be above 21 in at least three measurements, at different times in at least two different days during one month. 3. Visual acuity better than hand movements in the study eye. 4. Patients 18 years or more. 5. Patients with fixed residence in the health district where the surgery will be performed. 6. Patients who fit the term of consent. Exclusion Criteria:

Group post-trabeculectomy failure: 1. Presence of staphyloma that does not allow the procedure. 2. Presence of history of scleritis 3. Presence of psychiatric disorder that has required hospitalization. 4. Presence of retinal detachment surgery with placement of a buckle or track. 5. Presence of corneal opacity that could prevent the adequate view of the anterior chamber. 6. Presence of shallow anterior chamber that would prevent the placement of the implant. 7. Presence of vitreous in aphakia or anterior chamber. 8. Presence of psychiatric disorder that has required hospitalization. Neovascular glaucoma group: 1. Presence of staphyloma that does not allow the procedure. 2. Presence of history of scleritis. 3. Presence of corneal opacity that could prevent the adequate view of the anterior chamber. 4. Presence of shallow anterior chamber that would prevent the placement of the implant. 5. Presence of vitreous in aphakia or anterior chamber. 6. Presence of retinal detachment surgery with placement of a buckle or track. 7. Presence of neovascular glaucoma or other secondary glaucoma. 8. Presence of psychiatric disorder that has required hospitalization.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Adapt Produtos Oftalmológicos Ltda.
  • Provider of Information About this Clinical Study
    • PHC – Pharma Consulting, Dr. Dagoberto Brandão
  • Overall Official(s)
    • Remo Susanna, Investigator, Principal Investigator, Hospital das Clínicas de São Paulo
    • Renato Lisboa, Investigator, Principal Investigator, UNIFESP – Universidade Federal de São Paulo
    • Cláudia Galvão, Investigator, Principal Investigator, Hospital Universitário Prof. Edgar Santos – BA
    • Flávia Villas, Investigator, Principal Investigator, – Instituto brasileiro de Oftalmologia e prevenção da cegueira- BA
    • Fábio Kanadani, Investigator, Principal Investigator, Hospital Universitário São José – Belo Horizonte
    • Augusto Paranhos, Investigator, Principal Investigator, Hospital Israelita Albert Einstein
  • Overall Contact(s)
    • Augusto Paranhos, Investigator, 55 11 3747-3312

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.